Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Age at menarche is a strong and consistent predictor of breast cancer risk in the general population, but has not been well studied in women with a family history of breast cancer. We conducted this study to examine whether the presence of a deleterious BRCA1 or BRCA2 mutation influences age at menarche and to investigate whether or not there is an association between age at menarche and the risk of breast cancer in BRCA1 or BRCA2 mutation carriers. The presence of a deleterious BRCA1 or BRCA2 mutation did not appear to influence a woman’s age at menarche. A matched case–control study was conducted on 1311 pairs of women who have been identified to be carriers of a deleterious mutation in either the BRCA1 (n = 945 pairs) or the BRCA2 gene (n = 366 pairs). Information about age at menarche was derived from a questionnaire routinely administered to carriers of a mutation in either gene. Among women who carried a deleterious BRCA1 mutation, age at menarche was inversely associated with the risk of breast cancer (p trend = 0.0002). This association was not observed among BRCA2 mutation carriers (p trend = 0.49). Compared with BRCA1 carriers whose age at menarche was ≤11 years, women with a menarcheal age between 14 and 15 years old had a 54% reduction in risk (OR = 0.46; 95% CI 0.30–0.69). This study implicates early age at menarche as a determinant of breast cancer among women with a BRCA1 mutation. * Address correspondence to: Steven A. Narod, Centre for Research in Women’s Health, University of Toronto, 790 Bay Street, Room 750, 7th Floor, Women’s College Hospital, Toronto, Ontario, M5G 1N8, Canada. Ph.: +1-416-351-3765; Fax: +1-416-351-3767; E-mail: steven.narod@swchsc.on.ca